Everolimus-induced Lymphedema in a Renal Transplant Recipient: A Case Report
- 23 May 2012
- journal article
- case report
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 10 (3) , 296-298
Abstract
The mammalian target of rapamycin inhibitors is commonly preferred for solid organs for transplantation. Although these drugs have various adverse effects, sirolimus-related lymphedema has been rarely reported. We report a case of lymphedema related to everolimus after a kidney transplant. A 60-year-old woman successfully received a deceased-donor kidney. Everolimus was added to the treatment in postoperative month 3 owing to other immunosuppressive drugs' adverse effects. Edema occurred first on her feet in the first year after the transplant. During 3 months' follow-up, with no immunosuppressive adjustment, the edema progressed. Diagnosis of lymphedema was established. Several weeks after discontinuing everolimus, the patient's lymphedema began to resolve itself and completely disappeared in 3 months. The mammalian target of rapamycin inhibitors rarely causes lymphedema by inhibiting different subtypes of vascular endothelial growth factors, which results in impaired lymphangiogenesis. While there are few reports about sirolimus-related lymphedema, this case represents the first everolimus-related case of lymphedema. Further studies are warranted to explain the underlying mechanisms.Keywords
This publication has 10 references indexed in Scilit:
- Generalized lymphedema in a sirolimus‐treated renal transplant patientClinical Transplantation, 2007
- Subclinical rejection and sirolimus associated edema in renal allograft recipientsTransplant International, 2007
- Lymphedema: An Unusual Complication of Sirolimus TherapyTransplantation Proceedings, 2007
- Inhibition of the mammalian target of rapamycin impedes lymphangiogenesisKidney International, 2007
- Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGFBlood, 2005
- Immunosuppressive Therapy with Everolimus Can Be Associated with Potentially Life-Threatening Lingual AngioedemaTransplantation, 2005
- Severe Limb Lymphedema in Sirolimus-Treated PatientsTransplantation Proceedings, 2005
- Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factorNature Medicine, 2002
- Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3Nature Medicine, 2001
- Missense mutations interfere with VEGFR-3 signalling in primary lymphoedemaNature Genetics, 2000